There is no doubt that HCA Healthcare Inc. (HCA) ticks all the boxes.

HCA Healthcare Inc. (NYSE: HCA) stock fell -3.35% on Tuesday to $267.76 against a previous-day closing price of $277.04. With 1.17 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.32 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $274.40 whereas the lowest price it dropped to was $267.02. The 52-week range on HCA shows that it touched its highest point at $294.02 and its lowest point at $164.47 during that stretch. It currently has a 1-year price target of $311.81. With its current market cap of 72.86 billion, HCA has annualized dividend of $2.40 while the current yield stands at 0.90%. Beta for the stock currently stands at 1.65.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HCA was down-trending over the past week, with a drop of -2.83%, but this was down by -6.46% over a month. Three-month performance surged to 5.38% while six-month performance rose 16.38%. The stock gained 30.75% in the past year, while it has gained 11.59% so far this year. A look at the trailing 12-month EPS for HCA yields 19.95 with Next year EPS estimates of 19.87. For the next quarter, that number is 4.22. This implies an EPS growth rate of -9.50% for this year and 9.87% for next year. EPS is expected to grow by 8.03% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 23.10%.

Float and Shares Shorts:

At present, 276.91 million HCA shares are outstanding with a float of 210.77 million shares on hand for trading. On Apr 27, 2023, short shares totaled 2.21 million, which was 0.80% higher than short shares on Mar 30, 2023. In addition to Mr. Samuel N. Hazen as the firm’s CEO & Director, Mr. William B. Rutherford serves as its Exec. VP & CFO.

Institutional Ownership:

Through their ownership of 65.99% of HCA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 36.73% of HCA, in contrast to 33.77% held by mutual funds. Shares owned by individuals account for 28.94%. As the largest shareholder in HCA with 6.15% of the stake, The Vanguard Group, Inc. holds 17,042,919 shares worth 17,042,919. A second-largest stockholder of HCA, Wellington Management Co. LLP, holds 12,895,356 shares, controlling over 4.66% of the firm’s shares. Sanders Capital LLC is the third largest shareholder in HCA, holding 10,585,344 shares or 3.82% stake. With a 2.36% stake in HCA, the Vanguard Wellington Fund is the largest stakeholder. A total of 6,547,705 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.32% of HCA stock, is the second-largest Mutual Fund holder. It holds 6,432,038 shares valued at 1.85 billion. Vanguard 500 Index Fund holds 1.79% of the stake in HCA, owning 4,950,268 shares worth 1.42 billion.


An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, HCA reported revenue of $14.82B and operating income of $2.30B. The EBITDA in the recently reported quarter was $3.04B and diluted EPS was $3.90.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HCA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With HCA analysts setting a high price target of $350.00 and a low target of $266.00, the average target price over the next 12 months is $312.36. Based on these targets, HCA could surge 30.71% to reach the target high and fall by -0.66% to reach the target low. Reaching the average price target will result in a growth of 16.66% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded HCA stock several times over the past three months with 5 Buys and 9 Sells. In these transactions, 63,668 shares were bought while 80,037 shares were sold. The number of buy transactions has increased to 47 while that of sell transactions has risen to 70 over the past year. The total number of shares bought during that period was 638,797 while 496,066 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *